Active Tissue Inhibitors Of Metalloproteinase 3 (TIMP3)
SFD; TIMP Metallopeptidase Inhibitor 3; Metallopeptidase Inhibitor 3; Sorsby Fundus Dystrophy; Pseudoinflammatory
- Product No.APA129Bo01
- Organism SpeciesBos taurus; Bovine (Cattle) Same name, Different species.
- Buffer Formulation100mMNaHCO3, 500mMNaCl, pH8.3, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300.
- Traits Freeze-dried powder
- Purity> 90%
- Isoelectric Point9.4
- ApplicationsCell culture; Activity Assays.
- Downloadn/a
- UOM 10µg50µg 200µg 1mg 5mg
- FOB
US$
US$
US$
US$
US$
For more details, please contact local distributors!
ACTIVITY TEST
Tissue Inhibitors of Metalloproteinase 3 (TIMP3) is a key extracellular matrix protein encoded by the TIMP3 gene, playing pivotal roles in regulating matrix metalloproteinase (MMP) activity. It is widely expressed in various tissues, participating in tissue remodeling, angiogenesis, and inflammation. Dysregulation of TIMP3 is linked to multiple diseases, including cancer, cardiovascular disorders, and degenerative conditions, due to its ability to inhibit MMP-mediated extracellular matrix degradation. TIMP3 binds specifically to MMP9 with high affinity, forming a stable complex that potently suppresses MMP9’s proteolytic activity to maintain tissue homeostasis.Thus a functional ELISA assay was conducted to detect the interaction of recombinant cattle TIMP3 and recombinant human MMP9. Briefly, TIMP3 was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to MMP9-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-TIMP3 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37℃, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 µL stop solution to the wells and read at 450/630nm immediately. The binding activity of recombinant cattle TIMP3 and recombinant human MMP9 was shown in Figure 1, the EC50 for this effect is 0.83911µg/mL.
USAGE
Reconstitute in 100mM NaHCO3, 500mM NaCl (pH8.3) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
STORAGE
Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.
STABILITY
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
GIVEAWAYS
INCREMENT SERVICES
-
BCA Protein Quantification Kit
-
Molecular Mass Marker for Protein
-
Monoclonal Antibody Customized Service
-
Polyclonal Antibody Customized Service
-
Protein Activity Test Experiment Service
-
Electrophoretic Mobility Shift Assay (EMSA) Experiment Service
-
Buffer
-
Lentivirus Packaging Experiment Service
-
Adenovirus Packaging Experiment Service
-
Real Time PCR Experimental Service
-
Spike RBD Protein (S-RBD)
-
Protein G
-
Protein A
| Magazine | Citations |
| Neuroimmunomodulation | Upregulated Expression of Matrix Metalloproteinases and Tissue Inhibitors of Matrix Metalloproteinases in BALB/c Mouse Brain Challenged with Japanese Encephalitis Virus Pubmed: source |
| Experimental Biology and Medicine | Acidic pH conditions mimicking degenerative intervertebral discs impair the survival and biological behavior of human adipose-derived mesenchymal stem cells Rsmjournals: Source |
| PLoS ONE | A Combinatorial Relative Mass Value Evaluation of Endogenous Bioactive Proteins in Three-Dimensional Cultured Nucleus Pulposus Cells of Herniated Intervertebral Discs: Identification of Potential Target Proteins for Gene Therapeutic Approaches Plosone: Source |
| Physiol. Res. | The unwounded skin remodeling in animal models of diabetes types 1 and 2. Pubmed: 24020818 |
| VirusDisease | Circulating levels of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases during Japanese encephalitis virus infection Pubmed:26925446 |
| Acta Pharmacol Sin. | Pharmacological evidence: a new therapeutic approach to the treatment of chronic heart failure through SUR2B/Kir6.1 channel in endothelial cells. pubmed:27890915 |
| Biochemical genetics | Comparison of Selected Protein Levels in Tumour and Surgical Margin in a Group of Patients with Oral Cavity Cancer pubmed:28421310 |
| International Journal of Cancer | Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma Pubmed: 30650187 |
| J. Pers. Med | Altered TIMP-3 Levels in the Cerebrospinal Fluid and Plasma of Patients with Alzheimer's Disease Pubmed:35629249 |
